EcoDrugPlus

Isocitrate Dehydrogenase (Nadp(+)) 1

Ensembl ID : ENSBTAG00000020527
Gene Symbol: IDH1
9 Enzyme and pathways 4 Cross references
246 Possible Orthologues:

Isocitrate Dehydrogenase (Nadp(+)) 2

Ensembl ID : ENSBTAG00000014093
Gene Symbol: IDH2
7 Enzyme and pathways 5 Cross references
273 Possible Orthologues:

Kallikrein B1

Ensembl ID : ENSBTAG00000009501
Gene Symbol: KLKB1
6 Enzyme and pathways 5 Cross references
222 Possible Orthologues:

Kelch Like Ech Associated Protein 1

Ensembl ID : ENSBTAG00000003543
Gene Symbol: KEAP1
13 Enzyme and pathways 5 Cross references
201 Possible Orthologues:

Kinase Insert Domain Receptor

Ensembl ID : ENSBTAG00000000782
Gene Symbol: KDR
8 Enzyme and pathways 5 Cross references
211 Possible Orthologues:

Kinesin Family Member 11

Ensembl ID : ENSBTAG00000009383
Gene Symbol: KIF11
11 Enzyme and pathways 5 Cross references
214 Possible Orthologues:

Kinesin Family Member 5b

Ensembl ID : ENSBTAG00000002280
Gene Symbol: KIF5B
16 Enzyme and pathways 5 Cross references
300 Possible Orthologues:

Leukotriene A4 Hydrolase

Ensembl ID : ENSBTAG00000016415
Gene Symbol: LTA4H
16 Enzyme and pathways 5 Cross references
219 Possible Orthologues:

Leukotriene B4 Receptor

Ensembl ID : ENSBTAG00000010238
Gene Symbol: LTB4R
8 Enzyme and pathways 5 Cross references
152 Possible Orthologues:

Leukotriene B4 Receptor 2

Ensembl ID : ENSBTAG00000040056
Gene Symbol: LTB4R2
8 Enzyme and pathways 5 Cross references
250 Possible Orthologues:

Lysine Demethylase 1a

Ensembl ID : ENSBTAG00000009500
Gene Symbol: KDM1A
15 Enzyme and pathways 5 Cross references
226 Possible Orthologues:

Lysyl Oxidase Like 2

Ensembl ID : ENSBTAG00000006214
Gene Symbol: LOXL2
5 Enzyme and pathways 5 Cross references
300 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).